Manuel Ruíz Borrego

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung‐Bae Kim et al. · The Lancet · 2023 · 313 citations · Full text

Breast Oncology, Medicine, Clinical Trials +7

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

Miguel Martín, Miguel Ángel Seguí, Antonio Antón et al. · New England Journal of Medicine · 2010 · 208 citations · Full text

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Miguel Martín, A. Chan, Luc Dirix et al. · Annals of Oncology · 2016 · 178 citations · Full text

Breast Oncology, Medicine, Pharmacology +6